Gentian Diagnostics: Invitation to virtual presentation at 24 June

18. Jun 2021 | 2 min read

Gentian Diagnostics ASA has the pleasure of inviting to a virtual presentation
on Thursday 24 June 2021 at 10:00-11.00 am CEST in relation with the company’s
updated investor presentation and new long-term ambition (see separate stock exchange release earlier today).

Gentian’s CEO Hilja Ibert, CSO Erling Sundrehagen and CFO Njaal Kind will
present the company followed by a Q&A session.

Join the online presentation via the following link: 

Questions can be submitted during the online webcast.

IR contact
Njaal Kind, CFO 
+47 919 06 525 (mobile)

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures
high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies
within immunochemistry, specifically infections, inflammations, kidney failures
and congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is based in
Moss, Norway, serving the global human and veterinary diagnostics markets
through sales and representative offices in Sweden, USA and China. For more
information, please visit

You may also read

Jun 25, 2021 - Kristin Hart

Gentian Diagnostics was today listed on the Oslo Stock Exchange

“We made a promise to our shareholders when we were listed on Euronext Growth that we would aim for the main..

Jun 24, 2021 - Kristin Hart

Gentian Diagnostics ASA – Approval and publication of prospectus, and transfer of listing from Euronext Growth (Oslo) to Oslo Børs

Moss, 24 June 2021 Reference is made to the announcement made by Gentian Diagnostics ASA (the "Company") on 7..

Jun 23, 2021 - Kristin Hart

Transfer of shares to Oslo Børs approved, prepared for accelerated growth

Moss, 23.06.2021 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of innovative and..